76.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$76.40
Aprire:
$76.94
Volume 24 ore:
20.64M
Relative Volume:
1.32
Capitalizzazione di mercato:
$192.95B
Reddito:
$63.92B
Utile/perdita netta:
$17.43B
Rapporto P/E:
11.18
EPS:
6.87
Flusso di cassa netto:
$17.04B
1 W Prestazione:
-0.95%
1M Prestazione:
-9.29%
6M Prestazione:
-24.40%
1 anno Prestazione:
-38.30%
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Confronta MRK con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MRK
Merck Co Inc
|
76.84 | 194.81B | 63.92B | 17.43B | 17.04B | 6.87 |
![]()
LLY
Lilly Eli Co
|
737.67 | 640.72B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
155.21 | 367.98B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
186.11 | 323.71B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
115.76 | 222.69B | 53.22B | 12.86B | 14.85B | 6.39 |
![]()
NVO
Novo Nordisk Adr
|
71.50 | 299.26B | 43.59B | 15.04B | 10.74B | 3.3766 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
2025-01-08 | Downgrade | Truist | Buy → Hold |
2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2024-12-10 | Ripresa | BofA Securities | Buy |
2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
2024-10-17 | Iniziato | Bernstein | Mkt Perform |
2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
2023-11-09 | Iniziato | Deutsche Bank | Buy |
2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
2023-07-14 | Iniziato | HSBC Securities | Hold |
2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2023-03-06 | Iniziato | Jefferies | Buy |
2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
2022-11-18 | Iniziato | Credit Suisse | Outperform |
2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
2022-06-06 | Ripresa | SVB Leerink | Outperform |
2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
2021-12-17 | Iniziato | Goldman | Buy |
2021-12-16 | Iniziato | Daiwa Securities | Neutral |
2021-12-13 | Downgrade | UBS | Buy → Neutral |
2021-12-09 | Iniziato | Wells Fargo | Overweight |
2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
2021-11-01 | Aggiornamento | Argus | Hold → Buy |
2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-07-27 | Ripresa | Truist | Buy |
2021-05-20 | Downgrade | Argus | Buy → Hold |
2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
2020-11-10 | Ripresa | Bernstein | Outperform |
2020-09-29 | Iniziato | Berenberg | Hold |
2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2020-02-27 | Iniziato | Barclays | Overweight |
2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
2019-10-17 | Ripresa | BofA/Merrill | Neutral |
2019-08-16 | Iniziato | SVB Leerink | Outperform |
2019-07-03 | Iniziato | Mizuho | Buy |
2019-05-28 | Iniziato | Goldman | Neutral |
2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
2018-10-16 | Reiterato | Citigroup | Buy |
2018-10-09 | Ripresa | Guggenheim | Buy |
2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
FDA Action Alert: Merck, Moderna, Gilead, Regeneron/Sanofi and More - BioSpace
Merck's (MRK) Keytruda-Trodelvy Combo Shows Significant Benefits in Breast Cancer Treatment | MRK Stock News - GuruFocus
Gilead Sciences, Inc, (GILD)’s Trodelvy and Merck & Co., Inc, (MRK)’s Keytruda Cuts Breast Cancer Progression Risk by 35% - Insider Monkey
Merck & Co., Inc. (MRK)’s MK-1084 Shows Promise in Early Cancer Trial - Insider Monkey
Merck & Co., Inc. (MRK) Reports Positive Trial Results for DLBCL Drug - Insider Monkey
Merck Says Keytruda® Plus Trodelvy® Reduced Risk Of Disease Progression Or Death By 35% Versus Keytruda Plus Chemotherapy In First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer - marketscreener.com
ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small - insights.citeline.com
Jim Cramer on Merck & Co (MRK): ‘I’ve Got To Take a Hard Look At It’ - MSN
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers - Benzinga
Merck (MRK) Sees Promising Results in Cancer Drug Trial - GuruFocus
Merck releases positive early-stage data on colorectal cancer and NSCLC asset - Seeking Alpha
Merck (MRK) Antibody Drug Shows Promise in Lymphoma Trial - GuruFocus
Merck antibody drug conjugate asset shows antitumor activity in phase 2 - Seeking Alpha
Merck CEO Calls Diversity ‘Core’ to Operations as Anti-DEI Measure Is Defeated - BioSpace
Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - MSN
Merck Reports Antitumor Activity With Experimental KRAS Inhibitor MK-1084 in Early Trial - marketscreener.com
Merck Says Potential Lymphoma Therapy Achieves 56.3% Response Rate in Phase 2 Study - marketscreener.com
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor - marketscreener.com
Merck (MRK) Reports Promising Phase 2/3 Trial Results for Cancer Therapy | MRK Stock News - GuruFocus
Merck reports promising results for cancer drug MK-1084 By Investing.com - Investing.com India
Merck reports promising DLBCL treatment results By Investing.com - Investing.com India
Merck reports promising results for cancer drug MK-1084 - Investing.com
Here’s Why Merck & Co. (MRK) Traded Lower in Q1 - Insider Monkey
Merck reports promising DLBCL treatment results - Investing.com
Merck'S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity - marketscreener.com
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial - Business Wire
Merck’s West Point Presence Remains Strong Amid Riverside Closure - BUCKSCO.Today
Transcript : Merck & Co., Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 03 - marketscreener.com
Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - Yahoo Finance
Bernstein 41st Annual Strategic Decisions Conference - Merck.com
Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS - insights.citeline.com
Merck & Co To Present At Bernstein Strategic Decisions Conference; Webcast At 3:30 PM ET - Nasdaq
Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer - Reuters
Merck & Co. Concludes Annual Shareholders Meeting - TipRanks
Merck shareholders approve board, executive pay at annual meeting By Investing.com - Investing.com India
Merck shareholders approve board, executive pay at annual meeting - Investing.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Merck, Daiichi pull approval application for ADC in lung cancer - BioPharma Dive
Merck: voluntary withdrawal of a BLA in lung cancer - marketscreener.com
Is Merck Stock Underperforming the Nasdaq? - MSN
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck (MRK) and Daiichi Sankyo Withdraw U.S. Application for Lung Cancer Therapy - GuruFocus
Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw - marketscreener.com
Is Merck Stock Underperforming The Nasdaq? - Barchart.com
Merck (MRK) Withdraws Biologics License Application for Patritum - GuruFocus
Merck stock drops as BLA for lung cancer drug is pulled (MRK) - Seeking Alpha
Merck Withdraws Biologics License Application for Patritumab Deruxtecan - marketscreener.com
Major Setback: Merck's Advanced Lung Cancer Drug Falls Short in Crucial Survival Trial - Stock Titan
Abbisko Secures $85 Million from Merck for Pimicotinib Global Rights - TipRanks
Dow falls nearly 250 points on losses in Merck, Nike shares - MSN
Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market | DelveInsight - PR Newswire UK
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):